ARIBIO
Business Services · South Korea · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Seoul-incheon Route Yeongdeungpo-gu, Seo...Phone Number
+82 226370009Website
www.aribio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About ARIBIO
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer's disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the field of medicine.Explore more
ARIBIO Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ARIBIO your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
ARIBIO, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at ARIBIO
Check out if ARIBIO is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when ARIBIO launches new products
Earning: See what the market has to say on ARIBIO recently announced quarterly report
Funding: Get notified immidiatlly once ARIBIO has new funding data
Check if ARIBIO has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Click to see if ARIBIO had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at ARIBIO
Find 3 more new buyers
Company Profile Activity
Activity Insights
ARIBIO is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ARIBIO is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ARIBIO.
ARIBIO Tech Stack
A closer look at the technologies used by ARIBIO
See more technologies
ARIBIO News & Media
AriBio and RESTARI Announce Exclusive License Agreement for a Novel Program in Polycystic Kidney Disease and Cystic Liver Diseases
AriBio Co., Ltd., a Phase 3 biopharmaceutical company, RESTARI, a company focused on severe kidney diseases, today announced that the companies have entered into an exclusive license and commercialization agreement for the development of a small molecule for certain indications related to...AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer’s Disease
Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) -- AriBio Co., Ltd. ("AriBio"), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively “Arcera”), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer’s disease.Neurophet joins with AriBio to drive AI-powered Alzheimer’s detection
The deal between the two companies aims to develop an artificial intelligence driven platform designed to cut out PET scans.Adaptive Research Announces it has Begun Enrolling Patients in AriBio’s Phase 3 POLARIS-AD Clinical Trial
Adaptive Research announced it has begun enrolling patients in AriBio’s Phase 3 POLARIS-AD Clinical Trial.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding ARIBIO
Sign Up For FreeTo access detailed company insights
AriBio Co., Ltd. is a biopharmaceutical company based in South Korea with offices in the United States. The company focuses on the development of novel therapies for neurodegenerative diseases including Alzheimer's disease. The company continues to expand its partnerships to accelerate best-in-class treatment options and further advancements in the... Read More
